Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV

Journal article

Ogbe A. et al, (2022), JCI Insight, 7

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

Journal article

Clemens SAC. et al, (2021), Nature Communications, 12

Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection

Journal article

Feng S. et al, (2021), Nature Medicine, 27, 2032 - 2040

ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.

Journal article

Fischer RJ. et al, (2021), Nature communications, 12

No one is safe until we are all safe.

Journal article

Gilbert S. and Hatchett R., (2021), Science translational medicine, 13

Recombinant protein vaccines against SARS-CoV-2.

Journal article

Gilbert SC. and Lambe T., (2021), The Lancet. Infectious diseases, 21, 1337 - 1338

Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models.

Journal article

van Doremalen N. et al, (2021), Science translational medicine, 13

Load More